专利号:US-12390420-B1 优先权日:2024-10-22 标题 :Compositions for targeted delivery of therapeutic agents and methods for the synthesis and use thereof 发明人:EGUCHI MASAKATSU 权利人:BRYET US INC 摘要:The present disclosure provides compositions and methods for delivering therapeutic agents to particular tissues or cells in a subject. The composition disclosed herein combines unique properties of porous micro- or nano-particles with host-guest chemistry provided by functionalized silicon particle, offering a versatile approach to addressing the challenges associated with delivering therapeutic agents to target tissues or sites within the body. The present disclosure also provides a method for synthesizing a composition capable of delivering therapeutic agents to particular tissues or cells in a subject.
1: Victorino APOS, Meton F, Mardegan L, Festa J, Piranda DN, Araujo KB. Trifluridine/tipiracil (FTD/TPI) and regorafenib in older patients with metastatic colorectal cancer. J Geriatr Oncol. 2023 May;14(4):101477. doi: 10.1016/j.jgo.2023.101477. Epub 2023 Mar 27. 14(9):e28665. doi: 10.7759/cureus.28665. 3: Blay JY, Duffaud F, George S, Maki RG, Penel N. Regorafenib for the Treatment of Sarcoma. Curr Treat Options Oncol. 2022 Nov;23(11):1477-1502. doi: 10.1007/s11864-022-00990-0. Epub 2022 Sep 30. 13:992611. doi: 10.3389/fimmu.2022.992611.
合成参考文献
参考文献:10.1007/s44211-022-00068-9 摘要:Li S, Jiang M, Li M, Hu P, Xu M, Shu C. Development and validation of a simple and sensitive HPLC method for the determination of related substances in regorafenib tablets. Anal Sci. 2022 Mar;38(3):591–9. doi: 10.1007/s44211-022-00068-9.